NeuroPace (NPCE) Change in Accured Expenses (2020 - 2026)
NeuroPace has reported Change in Accured Expenses over the past 7 years, most recently at -$4.0 million for Q1 2026.
- For Q1 2026, Change in Accured Expenses fell 71.24% year-over-year to -$4.0 million; the TTM value through Mar 2026 reached $1.9 million, up 1045.45%, while the annual FY2025 figure was $3.6 million, 355.17% up from the prior year.
- Change in Accured Expenses for Q1 2026 was -$4.0 million at NeuroPace, down from $1.0 million in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $2.6 million in Q3 2025 and troughed at -$4.0 million in Q1 2026.
- A 5-year average of $112823.5 and a median of $454000.0 in 2024 define the central range for Change in Accured Expenses.
- Biggest five-year swings in Change in Accured Expenses: skyrocketed 39975.0% in 2023 and later crashed 366.43% in 2024.
- Year by year, Change in Accured Expenses stood at -$136000.0 in 2022, then surged by 941.91% to $1.1 million in 2023, then plummeted by 124.8% to -$284000.0 in 2024, then skyrocketed by 459.86% to $1.0 million in 2025, then tumbled by 490.9% to -$4.0 million in 2026.
- Business Quant data shows Change in Accured Expenses for NPCE at -$4.0 million in Q1 2026, $1.0 million in Q4 2025, and $2.6 million in Q3 2025.